Novotech, Australia?s largest clinical CRO with offices throughout Asia, announced today the expansion of services to China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia.
Novotech, an Australian CRO with offices throughout Asia, announced the expansion of services to
China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia. Novotech Asia COO, Dr. John Moller said China is now the largest clinical trial destination in Asia, and the 5th largest in the world.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.